| Entry |
|
|---|
| Name |
Lisocabtagene maraleucel (USAN/INN);
Breyanzi (TN) |
|---|
| Product |
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic, Anti-CD19 CAR-T cell |
|---|
| Disease |
Diffuse large B-cell lymphoma, not otherwise specified [DS: H02434] Follicular lymphoma [DS: H01613] |
|---|
| Comment |
Cellular therapy product (CAR-T cell therapy)
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04662 | B cell receptor signaling pathway |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD19
D11990 Lisocabtagene maraleucel (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
Cellular and gene therapy products
D11990
New drug approvals in Japan [br08318.html]
Cellular and gene therapy products
D11990
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11990
|
|---|
| LinkDB |
|
|---|
